The development of highly efficient transition metal-catalyzed cross-coupling reactions has significantly benefited the synthesis of pharmaceuticals and agrochemicals. These transformations have demonstrated remarkable fidelity, but their success has led to an overreliance on producing structurally similar compounds, introducing bias in small molecule drug design. However, a new trend has emerged in recent years, aiming to design drugs with a greater number of sp -hybridized carbons that align more effectively with the 3D-shaped protein targets. This approach enhances the selectivity and efficacy of drugs while minimizing the potential for off-target side effects. Consequently, these insights have sparked a growing need for novel synthetic methods capable of incorporating sp -fragments. However, despite notable advancements in the field, introducing C(sp )-hybridized fragments through transitionmetal catalyzed cross-coupling reactions remains a significant challenge in organic synthesis.